SCHEMBL366812

SCHEMBL366812

CS(=O)(=O)NC(=O)c1ccc(OCc2ccc(F)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.63
BCL2L1 Q07817 2/20 0.62
MCL1 Q07820 2/20 0.62
NR4A2 P43354 1/20 0.61
PARP10 Q53GL7 1/20 0.59
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
LMNA P02545 1/20 0.57
RXFP1 Q9HBX9 1/20 0.57
HDAC1 Q13547 1/20 0.56
HDAC2 Q92769 1/20 0.56
ADAM17 P78536 2/20 0.55
MMP2 P08253 3/20 0.54
MMP9 P14780 2/20 0.54
MMP14 P50281 2/20 0.54
MMP1 P03956 1/20 0.54
ALDH1A1 P00352 2/20 0.53
MAPT P10636 2/20 0.53
MAPK1 P28482 1/20 0.53
HTT P42858 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14890621 0.88 GSK3B (0.55) MAOBBCL2L1MCL1NR4A2PARP10
SCHEMBL16239768 0.88 ALDH1A1 (0.70) BCL2L1MCL1LMNAADAM17ALDH1A1
SCHEMBL365645 0.88 ALDH1A1 (0.70) BCL2L1MCL1LMNAADAM17ALDH1A1
SCHEMBL364340 0.88 RXRA (0.62) BCL2L1MCL1NR4A2PARP10MEN1
SCHEMBL365210 0.86 MAOA (0.63) MAOBBCL2L1MCL1NR4A2MEN1
SCHEMBL366081 0.86 MAOA (0.63) MAOBBCL2L1MCL1NR4A2MEN1
SCHEMBL365173 0.86 MAOB (0.61) MAOBBCL2L1MCL1NR4A2PARP10
SCHEMBL366570 0.86 MMP1 (0.58) MAOBBCL2L1MCL1NR4A2HDAC1
SCHEMBL364950 0.86 MAOB (0.66) MAOBBCL2L1MCL1ALDH1A1MAPT
SCHEMBL364237 0.84 BCL2L1 (0.72) MAOBBCL2L1MCL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-2593428-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593428-A2 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130109701-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012007868-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109701-A1 Chemical Compounds SCN1A, SCN1B, SCN7A MAOB 3660/4885BCL2L1 3577/4885MCL1 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.